NO20072794L - Kjemiske forbindelser - Google Patents

Kjemiske forbindelser

Info

Publication number
NO20072794L
NO20072794L NO20072794A NO20072794A NO20072794L NO 20072794 L NO20072794 L NO 20072794L NO 20072794 A NO20072794 A NO 20072794A NO 20072794 A NO20072794 A NO 20072794A NO 20072794 L NO20072794 L NO 20072794L
Authority
NO
Norway
Prior art keywords
chemical connections
sarsasapogenin
connections
chemical
solvated
Prior art date
Application number
NO20072794A
Other languages
English (en)
Inventor
Peter David Tiffin
Original Assignee
Phytopharm Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytopharm Plc filed Critical Phytopharm Plc
Publication of NO20072794L publication Critical patent/NO20072794L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)

Abstract

Oppfinnelsen tilveiebringer sarsasapogenin i nye amorfe, krystallinske, solvatiserte og hydratiserte former, og anvendelse derav i fremstillingen av farmasøytisk eller spiselig sarsasapogenin og dets derivater.
NO20072794A 2004-11-05 2007-06-01 Kjemiske forbindelser NO20072794L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0424528A GB0424528D0 (en) 2004-11-05 2004-11-05 Chemical compounds
PCT/GB2005/004266 WO2006048665A2 (en) 2004-11-05 2005-11-04 Polymorphs of sarsapogenin

Publications (1)

Publication Number Publication Date
NO20072794L true NO20072794L (no) 2007-07-31

Family

ID=33523268

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072794A NO20072794L (no) 2004-11-05 2007-06-01 Kjemiske forbindelser

Country Status (17)

Country Link
US (1) US20080194530A1 (no)
EP (2) EP1809650A2 (no)
JP (1) JP2008519020A (no)
KR (1) KR20070089798A (no)
CN (2) CN102219826A (no)
AU (1) AU2005300348A1 (no)
BR (1) BRPI0517648A (no)
CA (1) CA2584676A1 (no)
GB (1) GB0424528D0 (no)
IL (1) IL182879A0 (no)
MX (1) MX2007005473A (no)
NO (1) NO20072794L (no)
RU (1) RU2007119611A (no)
SG (1) SG158068A1 (no)
TW (1) TW200635941A (no)
WO (1) WO2006048665A2 (no)
ZA (1) ZA200703630B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120034193A1 (en) 2009-01-24 2012-02-09 Daryl Rees Treatment of neurotrophic factor mediated disorders
US20130210786A1 (en) 2010-07-20 2013-08-15 Patrick Alexander Howson Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders
JP5881525B2 (ja) * 2011-05-16 2016-03-09 ライオン株式会社 サポゲニン安定化組成物の製造方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2306635A (en) * 1940-08-03 1942-12-29 Parke Davis & Co Method for the preparation of steroidal carbinols
US2408827A (en) * 1944-05-15 1946-10-08 Parke Davis & Co Steroidal compounds and methods for obtaining the same
US2774714A (en) * 1952-10-10 1956-12-18 Emanuel B Hershberg Process for the extraction of sapogenins from plant materials
US3019220A (en) * 1958-07-17 1962-01-30 Julian Lab Inc Isolation of sapogenins
US4057543A (en) * 1976-07-01 1977-11-08 G. D. Searle & Co. Process for the preparation of 17β-hydroxy-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone
US4680289A (en) 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
JPH04230696A (ja) * 1990-12-28 1992-08-19 Sanwa Shiyouyaku Kk 新規なステロイド系化合物および制癌剤
CN1033754C (zh) * 1993-05-31 1997-01-08 上海第二医科大学 知母皂甙元作为制备β肾上腺素和M胆碱受体双向调节药的用途及其制法
KR100217996B1 (ko) * 1996-12-23 1999-09-01 윤종용 프린트 헤드의 노즐 간격 보상 장치 및 방법
BR9909110A (pt) 1998-03-26 2000-12-12 Phytopharm Plc Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
AT409100B (de) 2000-07-24 2002-05-27 Evg Entwicklung Verwert Ges Vorrichtung zum schweissen einer drahtgittermatte
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
PL213697B1 (pl) * 2002-03-27 2013-04-30 Phytopharm Plc Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych

Also Published As

Publication number Publication date
CN101068827B (zh) 2011-06-08
MX2007005473A (es) 2007-05-24
KR20070089798A (ko) 2007-09-03
CA2584676A1 (en) 2006-05-11
WO2006048665A2 (en) 2006-05-11
EP1809650A2 (en) 2007-07-25
AU2005300348A1 (en) 2006-05-11
BRPI0517648A (pt) 2008-10-14
RU2007119611A (ru) 2008-12-10
EP2479183A3 (en) 2013-08-28
CN102219826A (zh) 2011-10-19
JP2008519020A (ja) 2008-06-05
US20080194530A1 (en) 2008-08-14
CN101068827A (zh) 2007-11-07
TW200635941A (en) 2006-10-16
WO2006048665A3 (en) 2006-09-08
EP2479183A2 (en) 2012-07-25
SG158068A1 (en) 2010-01-29
ZA200703630B (en) 2009-10-28
IL182879A0 (en) 2007-08-19
GB0424528D0 (en) 2004-12-08

Similar Documents

Publication Publication Date Title
NO20054905D0 (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
IL211084A0 (en) Single use module
NO20052591D0 (no) Pyridopyrolizin og pyridoindolizinderivater
NO20055204D0 (no) Derivater av piperidinyl- og pipemzinylalkylkarbamater, fremgangsmater for fremstilling derav og anvendelse av de samme i terapi
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
NO20051503D0 (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
NZ592897A (en) Crystals of laquinimod sodium, and process for the manufacture thereof
NO20053356L (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
JO2515B1 (en) Gamma-Crystalline form of ivabradine hydrochloride,a process for its preparation and pharmaceutical composition containing it
ATE393764T1 (de) Polymorphe formen von valsartan
NO20055686L (no) Sammensetning, fremgangsmate til fremstilling derav, og anvendelse derav.
NO20053569D0 (no) Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som nevrokininantagonister
DK2561880T3 (da) Mælkesyrebakterier som priobiotiske stammer og sammensætninger dermed
NO20072005L (no) Nye heterocykliske amider
UA91848C2 (ru) Применение соединений диосметина в лечении и предотвращении тромботическим патологиям
NO20055741L (no) Nye kjemiske forbindelser
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
NO20080133L (no) Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer
NO20082246L (no) Nye, umettede fettsyrederivater og dermokosmetologisk anvendelse derav
NO20050063L (no) 2-heteroaryl karboksamider
DE502004005907D1 (de) Selbstemulgierende wässrige polyurethandispersionen
IS7883A (is) Bakteríueyðandi indólón oxasólidínón, milliefni til framleiðslu þeirra og lyfjasametningar sem innihalda þau
IS8220A (is) Bensímídasólafleiður, blöndur sem innihalda þær, framleiðsla þeirra og notkun
NO20072794L (no) Kjemiske forbindelser
NO20053809D0 (no) Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application